Traité de virologie médicale, 2003. ,
Endocytosis of HIV: anything goes, Trends in Microbiology, vol.18, issue.12, pp.543-51, 2010. ,
DOI : 10.1016/j.tim.2010.09.003
Structure and Function of HIV-1 Reverse Transcriptase: Molecular Mechanisms of Polymerization and Inhibition, Journal of Molecular Biology, vol.385, issue.3, pp.693-713, 2009. ,
DOI : 10.1016/j.jmb.2008.10.071
Tackling tat, Journal of Molecular Biology, vol.293, issue.2, pp.235-54, 1999. ,
DOI : 10.1006/jmbi.1999.3060
Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells, Cell, vol.59, issue.1, pp.103-115, 1989. ,
DOI : 10.1016/0092-8674(89)90873-8
Host factors involved in retroviral budding and release, Nature Reviews Microbiology, vol.24, issue.7, pp.519-550, 2011. ,
DOI : 10.1038/nrmicro2596
Identification of a new human immunodeficiency virus type 1 distinct
from group M and group O, Nature Medicine, vol.10, issue.9, pp.1032-1039, 1998. ,
DOI : 10.1038/381661a0
A new human immunodeficiency virus derived from gorillas, Nature Medicine, vol.24, issue.8, pp.871-873, 2009. ,
DOI : 10.1038/nm.2016
Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic Implications, Journal of Virology, vol.81, issue.19, pp.81-10209, 2007. ,
DOI : 10.1128/JVI.00872-07
The hidden HIV epidemic : what do mathematical models tell us ? The case of France, Conférence de l'International AIDS Society, 2012. ,
Prise en charge médicale des personnes infectées par le VIH. 2010. 16. HAS, Dépistage de linfection par le VIH en France : Stratégies et dispositif de dépistage, p.44, 2009. ,
HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review, The Lancet Infectious Diseases, vol.11, issue.10, pp.11-769, 2011. ,
DOI : 10.1016/S1473-3099(11)70141-4
Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV ,
Transmitted virus with substitutions at position 215 and risk of virological failure in antiretroviral naive patients starting highly active antiretroviral therapy. XI International HIV drug resistance workshop : basic principles and clinical implications, pp.2-5, 2002. ,
Effect of baseline 215D/C/S « revertant » mutations on virological response to lamivudine /zidovudine-containing regimens and emergence of 215Y upon virological failure. XI International HIV drug resistance workshop : basic principles and clinical implications, pp.2-5, 2002. ,
Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons, Proceedings of the National Academy of Sciences, vol.98, issue.24, pp.13907-13912, 2001. ,
DOI : 10.1073/pnas.241300698
Evolution of amino acid 215 in HIV-1 reverse transcriptase in response to intermittent drug selection. XII International HIV drug resistance workshop : basic principles and clinical implications, pp.10-14, 2003. ,
Presence of thymidine associated mutations and response to d4T, abacavir and ddi in the control arm of the Narval ANRS 088 trial, th Conference on Retroviruses and opportunistic Infections. 4-8 february, 2001. ,
Impact of stavudine phenotype and thymidine analogs mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial, Antiviral Therapy, vol.7, issue.3, pp.211-218, 2002. ,
A Novel Genetic Pathway of Human Immunodeficiency Virus Type 1 Resistance to Stavudine Mediated by the K65R Mutation, Journal of Virology, vol.77, issue.10, pp.5685-93, 2003. ,
DOI : 10.1128/JVI.77.10.5685-5693.2003
Clinically relevant interpretation of genotype for resistance to abacavir, AIDS, vol.17, issue.12, pp.1795-802, 2003. ,
DOI : 10.1097/00002030-200308150-00008
Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutation Selection during In Vitro Exposure to Tenofovir Alone or Combined with Abacavir or Lamivudine, Antimicrobial Agents and Chemotherapy, vol.48, issue.4, pp.1413-1418, 2004. ,
DOI : 10.1128/AAC.48.4.1413-1415.2004
Multivariate analyses of antiviral response to tenofovir DF therapy in antiretroviralexperienced patients. XI International HIV drug resistance workshop : basic principles and clinical implications, pp.2-5, 2002. ,
Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903*, HIV Medicine, vol.35, issue.7, pp.442-50, 2006. ,
DOI : 10.1097/00002030-200401230-00012
K65R : a multi-nucleoside resistance mutation of a low but increasing frequency. XII International HIV drug resistance workshop : basic principles and clinical implications, pp.10-14, 2003. ,
Genotypic and pharmacological determinants of the virological response to tenofovir in nucleoside reverse transcriptase inhibitorexperienced patients, Antivir Ther, vol.9, issue.3, pp.315-338, 2004. ,
Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine, Journal of Medical Virology, vol.36, issue.4, pp.507-511, 1999. ,
DOI : 10.1002/(SICI)1096-9071(199912)59:4<507::AID-JMV14>3.0.CO;2-C
Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy, AIDS, vol.13, issue.13, pp.1705-1709, 1999. ,
DOI : 10.1097/00002030-199909100-00014
Pre-steady state kinetic analysis of the incorporation of FTC 5-monophosphate and 3TC 5-monophosphate by mutants HIV-1 RTs K65R, K65R/Q151M and Q151M. 16 th International Conference on Antiviral Research, 2003. ,
Clinically Relevant Genotype Interpretation of Resistance to Didanosine, Antimicrobial Agents and Chemotherapy, vol.49, issue.5, pp.1739-1783, 2005. ,
DOI : 10.1128/AAC.49.5.1739-1744.2005
An additive/substractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients, Journal of Clinical Virology, vol.36, issue.1, pp.36-42, 2006. ,
DOI : 10.1016/j.jcv.2006.01.008
Standardization and Clinical Relevance of HIV Drug Resistance Testing Project of the Forum for Collaborative HIV Research.Initiatives for Developing and Comparing Genotype Interpretation Systems: External Validation of Existing Systems for Didanosine against Virological Response, J Infect Dis, 2008. ,
TAMs in HIV-1 RT associated with reduced response to tenofovir DF in antiretroviral-experienced patients, 13 th Conference on Retroviruses and opportunistic Infections. 5-8 february, p.633, 2006. ,
Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase, Antiviral Research, vol.75, issue.3, pp.210-218, 2007. ,
DOI : 10.1016/j.antiviral.2007.03.006
Adefovir HIV-1 RT mutation K70E in the age of tenofovir. XIV International HIV Drug Resistance Workshop: basic principles and clinical implications, 2005. ,
Molecular Mechanism by Which the K70E Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Nucleoside Reverse Transcriptase Inhibitors, Antimicrobial Agents and Chemotherapy, vol.51, issue.1, pp.48-53, 2007. ,
DOI : 10.1128/AAC.00683-06
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy, AIDS, vol.14, issue.2, pp.163-171, 2000. ,
DOI : 10.1097/00002030-200001280-00012
Abacavir Once or Twice Daily Combined With Once-Daily Lamivudine and Efavirenz for the Treatment of Antiretroviral-Naive HIV-Infected Adults, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.38, issue.4, pp.417-442, 2005. ,
DOI : 10.1097/01.qai.0000147521.34369.c9
Treatment-emergent mutations for previously naïve HIV-infected adults failing ZDV+3TC+EFV and ABC+3TC+EFV (CNA30024). 11 th Conference on Retroviruses and Opportunistic Infections, 2004. ,
The NEAT Study: A 48-Week Open-Label Study to Compare the Antiviral Efficacy and Safety of GW433908 Versus Nelfinavir in Antiretroviral Therapy???Naive HIV-1-Infected Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.35, issue.1, pp.22-32, 2004. ,
DOI : 10.1097/00126334-200401010-00003
SOLO, AIDS, vol.18, issue.11, pp.1529-1566, 2004. ,
DOI : 10.1097/01.aids.0000131332.30548.92
Risk Factors for Selection of the L74I Reverse Transcriptase Mutation in Human Immunodeficiency Virus Type 1-Infected Patients, Antimicrobial Agents and Chemotherapy, vol.50, issue.7, pp.2553-2559, 2006. ,
DOI : 10.1128/AAC.00092-06
A Novel Genetic Pathway of Human Immunodeficiency Virus Type 1 Resistance to Stavudine Mediated by the K65R Mutation, Journal of Virology, vol.77, issue.10, 2003. ,
DOI : 10.1128/JVI.77.10.5685-5693.2003
Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine, Journal of Clinical Virology, vol.41, issue.4, pp.310-313, 2008. ,
DOI : 10.1016/j.jcv.2007.12.015
The K65R mutation subtype B and C HIV-1: rates of development and the implications of template-specific dislocation mutagenesis, Antiviral Therapy, vol.15, issue.2, p.13, 2010. ,
Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients, AIDS, vol.23, issue.1, pp.95-104, 2009. ,
DOI : 10.1097/QAD.0b013e328319bc91
Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors, AIDS, vol.19, issue.6, pp.549-54, 2005. ,
DOI : 10.1097/01.aids.0000163930.68907.37
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors, AIDS, vol.17, issue.1, pp.1-5, 2003. ,
DOI : 10.1097/00002030-200301030-00001
Resistance Mutations in Subtype C HIV Type 1 Isolates from Indian Patients of Mumbai Receiving NRTIs Plus NNRTIs and Experiencing a Treatment Failure: Resistance to AR, AIDS Research and Human Retroviruses, vol.23, issue.2, pp.335-375, 2007. ,
DOI : 10.1089/aid.2006.0183
Impact of baseline NNRTI mutations on the virological response to TMC125 in the Phase III clinical trials DUET-1 and DUET-2. XVI International HIV drug resistance workshop : basic principles and clinical implications, pp.12-16, 2007. ,
Factors Associated with Virological Response to Etravirine in Nonnucleoside Reverse Transcriptase Inhibitor-Experienced HIV-1-Infected Patients, Antimicrobial Agents and Chemotherapy, vol.54, issue.1, pp.72-79, 2010. ,
DOI : 10.1128/AAC.01051-09
Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies, AIDS, vol.24, issue.4, pp.503-517, 2010. ,
DOI : 10.1097/QAD.0b013e32833677ac
Impact of transmitted drug resistance (TDR) on virological response to initial combination antiretroviral therapy (cART), Antiviral Therapy, vol.15, issue.2, p.125, 2010. ,
In vitro selection of novel etravirine-associated resistance mutations in B and non-B HIV-1 subtypes, Antiviral Therapy, vol.15, issue.2, p.134, 2010. ,
TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1, Antimicrobial Agents and Chemotherapy, vol.54, issue.2 ,
DOI : 10.1128/AAC.00986-09
Mutations selected in patients displaying treatment failure under an etravirine-containing regimen, Antiviral Therapy, vol.10, pp.3851-1886, 2011. ,
Resistance-Associated Mutations to Etravirine (TMC-125) in Antiretroviral-Naive Patients Infected with Non-B HIV-1 Subtypes, Antimicrobial Agents and Chemotherapy, vol.54, issue.2, pp.728-761, 2010. ,
DOI : 10.1128/AAC.01335-09
Characterization of the E138K Resistance Mutation in HIV-1 Reverse Transcriptase Conferring Susceptibility to Etravirine in B and Non-B HIV-1 Subtypes, Antimicrobial Agents and Chemotherapy, vol.55, issue.2, pp.600-607, 2011. ,
DOI : 10.1128/AAC.01192-10
Characterization of the resistance profile of TMC278: 48-week analysis of the Phase III studies ECHO and THRIVE ,
Impact of HIV-1 reverse transcriptase E138 mutations selected on rilpivirine drug susceptibility, Antiviral Therapy, vol.16, issue.1, p.18, 2011. ,
Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir, Journal of Antimicrobial Chemotherapy, vol.61, issue.6, pp.1362-1370, 2008. ,
DOI : 10.1093/jac/dkn127
Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients, Antimicrobial Agents and Chemotherapy, vol.49, issue.5, pp.1720-1726, 2005. ,
DOI : 10.1128/AAC.49.5.1720-1726.2005
The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir???ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients, Journal of Clinical Virology, vol.38, issue.2, pp.131-139, 2007. ,
DOI : 10.1016/j.jcv.2006.11.011
URL : https://hal.archives-ouvertes.fr/hal-00690759
Human Immunodeficiency Virus Type 1 Genotypic and Pharmacokinetic Determinants of the Virological Response to Lopinavir-Ritonavir-Containing Therapy in Protease Inhibitor-Experienced Patients, Antimicrobial Agents and Chemotherapy, vol.46, issue.9, pp.2926-2932, 2002. ,
DOI : 10.1128/AAC.46.9.2926-2932.2002
Identification of I50L as the Signature Atazanavir (ATV)???Resistance Mutation in Treatment???Naive HIV???1???Infected Patients Receiving ATV???Containing Regimens, The Journal of Infectious Diseases, vol.189, issue.10, pp.1802-1812, 2004. ,
DOI : 10.1086/386291
Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients, AIDS, vol.20, issue.1, pp.35-40, 2006. ,
DOI : 10.1097/01.aids.0000196179.11293.fc
Identification and Structural Characterization of I84C and I84A Mutations That Are Associated with High-Level Resistance to Human Immunodeficiency Virus Protease Inhibitors and Impair Viral Replication, Antimicrobial Agents and Chemotherapy, vol.51, issue.2, pp.732-737, 2007. ,
DOI : 10.1128/AAC.00690-06
Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients, Antivir Ther, vol.12, issue.2, pp.247-52, 2007. ,
Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients, Antimicrobial Agents and Chemotherapy, vol.52, issue.9, 2008. ,
DOI : 10.1128/AAC.00133-08
Different substitutions under selective pressure at protease codon 82 in HIV-1 subtype G compared to subtype B infected individuals including a novel I82M resistance mutation. XIV International HIV Drug Resistance Workshop: basic principles and clinical implications, pp.7-11, 2005. ,
External Validation of Atazanavir/Ritonavir Genotypic Score in HIV-1 Protease Inhibitor-Experienced Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.PAP, issue.1, pp.127-135, 2006. ,
DOI : 10.1097/01.qai.0000219776.27798.e7
The Neat Study: Virologic response in subjects receiving GW433908 (908) BID by viral load/CD4 cell Counts at study entry, XV International AIDS Conference, 2004. ,
Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients, Antimicrob Agents Chemother, vol.51, issue.4, pp.1473-80, 2007. ,
Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen, AIDS, vol.18, issue.14, pp.1965-1971, 2004. ,
DOI : 10.1097/00002030-200409240-00016
Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance, AIDS, vol.20, issue.7, pp.1071-1075, 2006. ,
DOI : 10.1097/01.aids.0000222084.44411.cc
Resistance Profile of Darunavir: Combined 24-Week Results from the POWER Trials, AIDS Research and Human Retroviruses, vol.24, issue.3, pp.379-88, 2008. ,
DOI : 10.1089/aid.2007.0173
A novel genetic pathway involving L76V and M46I leading to lopinavir/r resistance. XVI International HIV drug resistance workshop : basic principles and clinical implications, pp.12-16, 2007. ,
Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy, Antimicrobial Agents and Chemotherapy, vol.53, issue.7, pp.2934-2943, 2009. ,
DOI : 10.1128/AAC.01643-08
Genotypic Resistance Analysis of the Virological Response to Fosamprenavir-Ritonavir in Protease Inhibitor-Experienced Patients in CONTEXT and TRIAD Clinical Trials, Antimicrobial Agents and Chemotherapy, vol.52, issue.12, pp.4251-4258, 2008. ,
DOI : 10.1128/AAC.00514-08
Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial, HIV Medicine, vol.10, issue.10, 2009. ,
DOI : 10.1111/j.1468-1293.2009.00734.x
A rigorous statistical learning method for the estimation and validation of weighted drug susceptibility scores applied to in vivo virological outcome prediction in atazanavir/ritonavir-containing HAART. XVII International HIV drug resistance workshop : basic principles and clinical implications, pp.10-14, 2008. ,
No effect of subtype on susceptibility and virological response to TPV/r for treatment experienced patients. XVII International HIV drug resistance workshop : basic principles and clinical implications, pp.10-14, 2008. ,
Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients, Journal of Antimicrobial Chemotherapy, vol.63, issue.3, pp.585-92, 2009. ,
DOI : 10.1093/jac/dkn544
Influence of Baseline Protease Inhibitor Resistance on the Efficacy of Darunavir/Ritonavir or Lopinavir/Ritonavir in the TITAN Trial, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.49, issue.5, pp.563-567, 2008. ,
DOI : 10.1097/QAI.0b013e318183ac9c
Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and 2. XVII International HIV drug resistance workshop : basic principles and clinical implications, pp.10-14, 2008. ,
Confirmation of the negative impact of protease mutations I47V, I54M, T74P and I84V and the positive impact of protease mutation V82A on virological response to darunavir/ritonavir. XVII International HIV drug resistance workshop : basic principles and clinical implications, pp.9-13, 2009. ,
Subgroup analysis of baseline susceptibility and early virological response to enfuvirtide in the combined TORO studies. XII International HIV drug resistance workshop : basic principles and clinical implications, pp.10-14, 2003. ,
Impact of HIV-1 gp41 amino acid substitutions (position 36-45) on susceptibility to T20 (enfuvirtide) in vitro ; analysis of primary virus isolates recovered from patients during chronic enfuvirtide treatment and site-directed mutants in NL4-3. XI International HIV drug resistance workshop : basic principles and clinical implications, pp.2-5, 2002. ,
Enfuvirtide (T-20) and T-1249 resistance : observations from phase II clinical trials of enfuvirtide in combination with oral antiretrovirals and a phase I/II dose-ranging monotherapy trial of T-1249. XI International HIV drug resistance workshop : basic principles and clinical implications, pp.2-5, 2002. ,
Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 to 24 weeks, 10 th Conference on Retroviruses and Opportunistic Infections, 2003. ,
Replicative fitness of HIV-1 strains with reduced susceptibility to protease-, reverse transcriptase-and entry (enfuvirtide)-inhibitors. XIII International HIV drug resistance workshop : basic principles and clinical implications, pp.8-12, 2004. ,
Development of a new genotypic resistance assay involving the entire gp41 sequence for evaluating resistance to enfuvirtide. XIII International HIV drug resistance workshop : basic principles and clinical implications, pp.8-12, 2004. ,
Evolution of enfurvitide resistance in longitudinal samples obtained after continued enfuvirtide dosing post-virological failure. XIV International HIV Drug Resistance Workshop: basic principles and clinical implications, 2005. ,
Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection, New England Journal of Medicine, vol.359, issue.4, pp.355-65, 2008. ,
DOI : 10.1056/NEJMoa0708978
Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro, Antimicrobial Agents and Chemotherapy, vol.52, issue.4, 2008. ,
DOI : 10.1128/AAC.01228-07
Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.54, issue.4, pp.389-93, 2010. ,
DOI : 10.1097/QAI.0b013e3181c42ea4
HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens, Journal of Antimicrobial Chemotherapy, vol.65, issue.6 ,
DOI : 10.1093/jac/dkq099
URL : https://hal.archives-ouvertes.fr/hal-00594696
Virological response and resistance in multi-experienced patients treated by raltegravir. XVII International HIV drug resistance workshop : basic principles and clinical implications, pp.10-14, 2008. ,
Evolution of resistance to the HIV integrase inhibitor (INI) elvitegravir can involve genotypic switching among primary INI resistance patterns. XVII International HIV drug resistance workshop : basic principles and clinical implications, pp.9-13, 2009. ,
Prevalence and patterns of raltegravir resistance in treated patients in Europe, Antiviral Therapy, vol.15, issue.2, p.62, 2010. ,
Comparison of Raltegravir Susceptible and Resistant Viruses Define the Contribution of Secondary Mutations to Reductions in Raltegravir Susceptibility, 17 th Conference on Retroviruses and Opportunistic Infection, 2010. ,
Identification of alternative amino acid substitutions at HIV-1 integrase codon 143 that confer reduced susceptibility to raltegravir, 18th Conference on Retroviruses and Opportunistic Infections, 2011. ,
In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, Antimicrobial Agents and Chemotherapy, vol.55, issue.2, 2011. ,
DOI : 10.1128/AAC.01209-10
In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase, Antivir Ther, vol.10, issue.7, pp.861-866, 2005. ,
In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors, Antimicrobial Agents and Chemotherapy, vol.52, issue.4, pp.1545-1553, 2008. ,
DOI : 10.1128/AAC.01284-07
URL : https://hal.archives-ouvertes.fr/inserm-00263591
Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis, Antivir Ther, vol.9, issue.1, pp.57-65, 2004. ,
Antiretroviral drug resistance in non-subtype B, HIV-2 and SIV, Antivir Ther, vol.9, issue.1, pp.3-12, 2004. ,
Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen, AIDS, vol.22, issue.15, pp.2045-2051, 2008. ,
DOI : 10.1097/QAD.0b013e32830f4c7d
Raltegravir treatment response in an HIV-2 infected patient: a case report, AIDS, vol.22, issue.9, pp.1091-1098, 2008. ,
DOI : 10.1097/QAD.0b013e3282f9b165
Hot Spots of Integrase Genotypic Changes Leading to HIV-2 Resistance to Raltegravir, Antimicrobial Agents and Chemotherapy, vol.55, issue.3, pp.1293-1295, 2011. ,
DOI : 10.1128/AAC.00942-10